Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and research collaboration agreement with Indivior PLC. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
IPO Year:
Exchange: NASDAQ
Website: addextherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $30.00 | Neutral → Buy | H.C. Wainwright |
| 2/11/2022 | $28.00 → $21.00 | Buy | HC Wainwright & Co. |
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
20-F - Addex Therapeutics Ltd. (0001574232) (Filer)
NT 20-F - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
Fastest customizable press release news feed in the world
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20252. Consultative vote on the Compensation Report for the business year 20253. Appropria
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury recoveryEntered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryRegained rights to phase 2 mGlu2 PAM asset, ADX71149Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesStrategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disordersCash position of CHF 1.6 million at December 31, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. "Chronic cough remains a significant unmet medical need, particularly in patients suffering from idiopathic pulmonary fibrosis (IPF), where persistent coughing substantially impacts quality of li
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The study is designed to generate a robust early-stage clinical data package assessing safety, tolerability, a
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. "These important data in non-human primates together with previously reported guinea pig data demonstrates the therapeutic potential of our highly selective, orally available GABAB PAM," said Tim Dyer, CEO of Addex. "Chronic cough is a
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could be transformative in the treatment of anxiety and fear-related disorders, such as post-traumatic stress disorder (PTSD). In the study, scientists from the Center for Psychiatric Neurosciences (CNP, CHUV/UNIL)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. "The progression
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright & Co.") initially entered into on January 30, 2024. The at-the-market offering program enables Addex to offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $3.3 million through H.C. Wainwright & Co., as its sales agent. T
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025 Title: Addex Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Upd
Live Leadership Updates
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025. The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a
Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. "It's great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex
Live finance-specific insights
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury recoveryEntered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryRegained rights to phase 2 mGlu2 PAM asset, ADX71149Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesStrategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disordersCash position of CHF 1.6 million at December 31, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025 Title: Addex Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Upd
Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025. Tit
Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics Q1 2025 financial results and corporate update Date: June 19, 2025Time: 16:00 CEST (15:
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic coughRepositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recoveryRegained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics Full-Year 2024 financial results and corporate update Date: April 25, 2025Ti
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and provided a corporate update. "During the third quarter of 2024, Indivior selected a GABAB PAM drug candidate from our collaboration for development in substance use disorders, allowing us to select our
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright upgraded Addex Therapeutics from Neutral to Buy and set a new price target of $30.00
HC Wainwright & Co. reiterated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $21.00 from $28.00 previously
HC Wainwright & Co. initiated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $28.00
This live feed shows all institutional transactions in real time.
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13G/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13G/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13G/A - Addex Therapeutics Ltd. (0001574232) (Subject)